USA flag logo/image

An Official Website of the United States Government

Arrayed Microfluidic Device for Reconstituted Tissue Assays

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
76123
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
DE017432
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BELLBROOK LABS, LLC
5500 NOBEL DR, STE 230 MADISON, WI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2007
Title: Arrayed Microfluidic Device for Reconstituted Tissue Assays
Agency: HHS
Contract: 9R44CA133909-02
Award Amount: $867,575.00
 

Abstract:

DESCRIPTION (provided by applicant): There is a strong need in drug discovery for cellular assays that better predict human responses to drugs. A key technical hurdle has been the difficulty of incorporating complex tissue architecture and cellular microen vironments into an assay format that is compatible with the high throughput approaches used for early drug discovery. In this proposal we propose to develop and commercialize a Microfluidic Reconstituted Tissue Device (fF-RTD) that will enable more physiol ogically relevant cellular assays in a high throughput, automated format. The device is a tubeless, automatable array of microfluidic channels for co-culture of mammalian cells in adjacent compartments in a three-dimensional format. The unique liquid flow properties at the microscale enable the construction of a robust, highly reproducible two-compartment tissue model in a highly parallel fashion. This means that potential drug molecules can be tested for their effects on disease processes in the context of intact tissue as opposed to non-physiological monolayers of cells. In Phase I, we developed a prototype microfluidic device and used it to extend a well established model of mammary epithelial acinar morphogenesis into a two compartment tissue model inclu ding fibroblasts. We will use this mammary tissue model to establish the design parameters of the fF-RTD and to functionally validate it for robust high throughput tumorigenesis assays. Prototype devices will be fabricated from elastomeric polymer and opti mized designs will be fabricated from polystyrene. The plastic fF-RTD devices will be validated using assays for key tumorigenic processes, including cell proliferation, apoptosis, and invasion using mammary epithelial and stromal cell lines as well as pri mary cells. In situ immunocytochemistry methods and fluorescent imaging will be the key methods used for analysis. Finally, the fF-RTD will be fully validated for high throughput screening and drug discovery by optimizing its integration with standard auto mated liquid dispensing equipment. Cellular assays that are more predictive are greatly needed in the pharmaceutical industry to improve the success rate in clinical trials, and in biomedical research in general to increase our understanding of disease mec hanisms. In this proposal we plan to develop and commercialize a Microfluidic Reconstituted Tissue Device that will enable more physiologically relevant cellular assays in a high throughput, automated format.

Principal Investigator:

Steven A. Hayes
6082274508
STEVE.HAYES@BELLBROOKLABS.COM

Business Contact:

Robert G. Lowery
bob.lowery@bellbrooklabs.com
Small Business Information at Submission:

BELLBROOK LABS, LLC
5500 Nobel Drive Suite 250 MADISON, WI 53711

EIN/Tax ID: 043661356
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No